BML, Inc. (TYO:4694)

Market Cap	143.75B +18.5%
Revenue (ttm)	149.09B +5.5%
Net Income	7.56B +24.3%
EPS	196.62 +26.1%
Shares Out	37.48M
PE Ratio	19.50
Forward PE	17.78
Dividend	120.00 (3.13%)
Ex-Dividend Date	Mar 30, 2026

Volume	66,300
Average Volume	86,815
Open	3,855.00
Previous Close	3,835.00
Day's Range	3,820.00 - 3,875.00
52-Week Range	2,768.00 - 4,385.00
Beta	0.29
RSI	32.97
Earnings Date	May 8, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4694

Financial Performance

In fiscal year 2025, BML, Inc.'s revenue was 143.19 billion, an increase of 3.79% compared to the previous year's 137.96 billion. Earnings were 6.26 billion, an increase of 3.80%.